Table 2 Percent change decrease in albuminuria in Vonoprazan containing H pylori therapy vs Lansoprazole containing H pylori therapy.

From: Vonoprazan attenuates proteinuria in diabetic kidney disease through potential direct renal mechanism

Group II (vonoprazan)

N = 50

Group I (lansoprazole)

N = 50

p valve

 

Median (IQR)

Range

Median (IQR)

Range

 

Total ACR percent change decrease in all patients

30.85(21.98–37.5)

−7.44-64.37

8.88(3.11–20.12

−21.58-47.67

< 0.001

ACR percent change decrease in H pylori Ag negative after eradication

30.39(22.69–37.24)

−7.44-53.1

7.26(3.28–18.31)

−13.54-47.67

< 0.001

ACR percent change decrease in H pylori Ag positive after eradication

33.57(21.59–48.85)

0.66–64.37

9.61(3.11–21.91)

−21.58-37.33

0.001

Back to article page